CDMO & C-suite headwinds for 2026

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO/c-suite leaders from the CDMO space, who discuss the big headwinds for the pharmaceutical and biotechnology space for 2026.

Show features:

• Christiane Bardroff, Chief Operating Officer (COO) at Rentschler Biopharma SE
• Philip Macnabb, Chief Executive Officer at Curia
• Kaan-Fabian Kekec, Partner at Simon-Kucher‘s Healthcare & Life Sciences division
• Dirk T. Lange , Chief Executive Officer at Pyramid Pharma Services Bruce Thompson, CTO at Kincell Bio
• Bill Vincent, Biotech Entrepreneur, CEO, Board Member
• Derek Hennecke - founder, investor, board member
• Matthew Bio, CSO at Cambrex & President, Snapdragon Chemistry Stephen Dilly, CEO at Sonoma Biotherapeutics,
• Stephen Dilly, CEO at Sonoma Biotherapeutics,
• Bill Humphries, Chief Executive Officer at Medpharm
• Elisabeth Stampa, CEO at Medichem SL
• Kerstin Dolph, SVP of Manufacturing at Charles River Labs
• Eric Edwards, Chief Executive Officer at Phlow-USA
• Peter DeYoung, CEO at Piramal Pharma
• Ian Tzeng, Managing Director at L.E.K. Consulting
• Adam Siebert, Managing Director at L.E.K. Consulting
• J.D. Mowery, President CDMO Division Bora Pharmaceuticals
• Peter Belden President, US, Tjoapack
• Nick Fortin, CEO CODIS

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!